Roche announces the latest results of multiple bispecific antibodies and ADC therapies

Today, Roche announced that it will announce the clinical results of a series of innovative treatments for different blood diseases at this year's American Society of Hematology (ASH) annual meeting

The feature of bispecific antibodies is that they can target two different antigens at the same time.

At the ASH annual meeting, Roche will announce the key clinical trial results of mosunetuzumab in the treatment of patients with relapsed/refractory follicular lymphoma

The results described in the ASH summary showed that mosunetuzumab monotherapy showed anticancer activity in most patients

In terms of safety, cytokine release syndrome (CRS) is the most common adverse event, occurring in 44% of patients, most of which are grade 1 or 2

At the R&D Day event held a few days ago, Roche pointed out that based on these positive data, the company will submit a regulatory application for mosunetuzumab before the end of 2021

In addition to Mosunetuzumab, another CD20-targeting bispecific antibody glofitamab developed by the company has a unique 2:1 structure

The clinical trial data described in the ASH summary showed that glofitamab, as a single-agent therapy, achieved 81% ORR (n=43) and 70% complete metabolic remission in early clinical trials for the treatment of patients with relapsed/refractory follicular lymphoma Rate (CMR)

In terms of safety, CRS appeared in 66% of monotherapy patients and 79% of combination therapy patients, most of which were grade 1 or 2

Roche believes that these two bispecific therapies have the potential to become "first-in-class" and "best-in-class" therapies for the treatment of follicular lymphoma and diffuse large B-cell lymphoma

In addition, cevostamab is a bispecific antibody that targets the FcRH5 receptor

The latest clinical trial results in the ASH Abstract show that as of May 18, 2021, 160 patients with relapsed/refractory multiple myeloma who have received multiple previous treatments have received different doses of cevostamab

The results of the test showed that among the patients who received cevostamab above the target dose, the ORR of the subgroup of patients who had previously received CAR-T therapy was 36.

In addition to bispecific antibodies, the targeted CD79b antibody-conjugated drug Polivy (polatuzumab vedotin) is combined with a treatment program called R-CHP, a key phase 3 clinical trial for the first-line treatment of patients with diffuse large B-cell lymphoma The primary endpoint was reached in mid-range, and compared with the standard treatment of R-CHOP, the risk of disease progression or death was reduced by 27% (HR=0.

CD79b protein is specifically expressed in most B cells.

In this clinical trial, 879 patients received Polivy combination therapy or R-CHOP treatment

Reference materials:

[1] Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders.
Retrieved November 23, 2021, from https:// cor-2021-11-23.
htm

[2] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study.
Retrieved November 23, 2021, from https://ash.
confex.
com/ash/2021/webprogram/Paper145872.
html

[3] Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy.
Retrieved November 23, 2021, from https://ash.
confex.
com/ash/2021/webprogram/Paper148949.
html

[4] Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study.
Retrieved November 23, 2021, from https:// ash.
confex.
com/ash/2021/webprogram/Paper147983.
html

[5] Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL).
Retrieved November 23, 2021, from https://ash.
confex.
com/ash/2021/webprogram/Paper148778.
html

[6] The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Large Therapy in Patients with Previously Untreated Diffuse Cell Lymphoma.
Retrieved November 23, 2021, from https://ash.
confex.
com/ash/2021/webprogram/Paper154729.
html

(The original text has been deleted)